2-(benzyloxymethyl)-4-phenyloxazole | 1531649-87-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(benzyloxymethyl)-4-phenyloxazole
• 英文别名: 4-Phenyl-2-(phenylmethoxymethyl)-1,3-oxazole
• CAS: 1531649-87-2
• 化学式: C₁₇H₁₅NO₂
• 分子量: 265.312
• InChiKey: RTPSZNHQXSKHTC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  35.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(benzyloxymethyl)-4-phenyloxazole 在 三溴化硼 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 生成 2-(Bromomethyl)-4-phenyl-1,3-oxazole
  参考文献：
  名称：

  Design, synthesis and structure–activity relationships of substituted oxazole–benzamide antibacterial inhibitors of FtsZ

  摘要：

  The design, synthesis and structure-activity relationships of a series of oxazole-benzamide inhibitors of the essential bacterial cell division protein FtsZ are described. Compounds had potent anti-staphylococcal activity and inhibited the cytokinesis of the clinically-significant bacterial pathogen Staphylococcus aureus. Selected analogues possessing a 5-halo oxazole also inhibited a strain of S. aureus harbouring the glycine-to-alanine amino acid substitution at residue 196 of FtsZ which conferred resistance to previously reported inhibitors in the series. Substitutions to the pseudo-benzylic carbon of the scaffold improved the pharmacokinetic properties by increasing metabolic stability and provided a mechanism for creating pro-drugs. Combining multiple substitutions based on the findings reported in this study has provided small-molecule inhibitors of FtsZ with enhanced in vitro and in vivo antibacterial efficacy. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.11.002
• 作为产物：
  描述：

  苄氧基乙酸乙酯 在 氨 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 11.0h， 生成 2-(benzyloxymethyl)-4-phenyloxazole
  参考文献：
  名称：

  [EN] [6,6] FUSED BICYCLIC HDAC8 INHIBITORS
  [FR] INHIBITEURS DE HDAC8 BICYCLIQUE [6,6] FUSIONNÉE

  摘要：

  本发明涉及以下式I的化合物：及其药用可接受的盐、前药、溶剂合物、水合物、互变异构体、或其同分异构体，其中R1、R2、R2'、L、X、W、Y1、Y2、Y3和Y4如本文所述。

  公开号：

  WO2017040963A1

文献信息

• [6,6] fused bicyclic HDAC8 inhibitors
  申请人：Forma Therapeutics, Inc.

  公开号：US10029995B2

  公开（公告）日：2018-07-24

  The present invention is directed to compounds of Formula I: and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers or thereof, wherein R1, R2, R2′, L, X, W, Y1, Y2, Y3, and Y4 are described herein.

  本发明涉及式 I 的化合物： 及其药学上可接受的盐、原药、溶液剂、水合物、同分异构体或异构体，其中 R1、R2、R2′、L、X、W、Y1、Y2、Y3 和 Y4 如本文所述。
• [6,6] Fused bicyclic HDAC8 inhibitors
  申请人：FORMA Therapeutics, Inc.

  公开号：US10370343B2

  公开（公告）日：2019-08-06

  The present invention is directed to compounds of Formula I: and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers or thereof, wherein R1, R2, R2′, L, X, W, Y1, Y2, Y3, and Y4 are described herein.

  本发明涉及式 I 的化合物： 及其药学上可接受的盐、原药、溶液剂、水合物、同分异构体或异构体，其中 R1、R2、R2′、L、X、W、Y1、Y2、Y3 和 Y4 如本文所述。
• [6,6] FUSED BICYCLIC HDAC8 INHIBITORS
  申请人：Forma Therapeutics, Inc.

  公开号：US20170066729A1

  公开（公告）日：2017-03-09

  The present invention is directed to compounds of Formula I: and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers or thereof, wherein R 1 , R 2 , R 2 ′, L, X, W, Y 1 , Y 2 , Y 3 , and Y 4 are described herein.